This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Universitá Degli Studi Di Siena. Active years: 2013.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2013
Title: Adriano Angelucci: Innovator in Pharmaceutical Chemistry
Introduction
Adriano Angelucci is a notable inventor based in Siena, Italy. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of compounds for medical applications. His work focuses on innovative solutions for treating bone-related diseases and tumors.
Latest Patents
Adriano Angelucci holds a patent for a compound known as 4-substituted derivatives of pyrazolo[3,4-d]pyrimidine and pyrrolo[2,3-d]pyrimidine. This invention relates to a compound that has the formula (I) and is particularly useful in the treatment of bone-related diseases and tumors. His patent represents a significant advancement in therapeutic options available for these conditions. He has 1 patent to his name.
Career Highlights
Angelucci is affiliated with the Università Degli Studi di Siena, where he contributes to research and development in the field of medicinal chemistry. His academic background and research endeavors have positioned him as a key figure in his area of expertise.
Collaborations
Adriano Angelucci has collaborated with notable colleagues such as Silvia Schenone and Francesco Bondavalli. These partnerships have enhanced his research capabilities and have led to innovative developments in pharmaceutical applications.
Conclusion
Adriano Angelucci's work exemplifies the impact of innovative research in the pharmaceutical industry. His contributions continue to pave the way for advancements in the treatment of critical health issues.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile